Published in Gene Therapy Weekly, May 26th, 2005
According to recent research published in the journal Chembiochem, "the angiogenesis inhibitor PTK 787/ZK 222584 (PTK/ZK) blocks all known VEGF receptor (VEGFR) tyrosine kinases, including the lymphangiogenic VEGFR3, in the lower nanomolar range. From a panel of 100 kinases only platelet derived growth factor receptor (PDGFR), c-kit, and c-fms are inhibited beyond those in the nanomolar range."
"PTK/ZK functions as a competitive inhibitor at the ATP-binding site of the receptor kinase as shown here in kinetic experiments," noted H. Hess-Stumpp and colleagues, Schering AG,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.